Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2
NCT02907021
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Heart Failure
Breast Cancer
Interventions
DRUG:
standard-of-care treatments for LV impairment
Sponsor
Population Health Research Institute